PowerTOST sample size FDA full replicate T/R ratio at 85% [🇷 for BE/BA]

posted by Shuanghe  – Spain, 2016-01-25 18:49 (3783 d 02:20 ago) – Posting: # 15852
Views: 23,276

Hi all,

I just noticed some strange result when I was making sample size plot for FDA full replicate BE using Detlew's famous PowerTOST.

My understanding was that, with T/R ratio fixed (e.g., 90%), when ISCV increase from, say, 10% to 100%, sample size will increase with the increasing ISCV and reach a peak at ISCV=30% then sample size will decrease due to widened BE criteria and after a certain point size will increase again due to high variability. This is true when I tried T/R ratio of 95% or 90%. For example, this plot.

[image]

However, when I was trying T/R ratio of 85% (I know, weird and problematic ratio assumption for BE. Don't ask why. Let's just say that I had to do it), the size peak reached at ISCV=27-28%, not at 30%. See this picture.

[image]


Why is that? Since all other assumptions are same (e.g., T/R ratio is still 85%), when ISCV increased from e.g., 28% to 29% and 30%, shouldn't we need more subjects as the BE criteria is not widened yet?

If my understanding is correct, then maybe it's a bug of the package? If I'm wrong, could anyone explain it in plain English :-D ? Many thanks.


Edit: Category changed. [Helmut]

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
153 visitors (0 registered, 153 guests [including 25 identified bots]).
Forum time: 22:10 CEST (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5